PAG
CYTK icon

Private Advisor Group’s Cytokinetics CYTK Stock Holding History

Private Advisor Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$617K Buy
+7,242
New +$520K ﹤0.01% 1646
2020
Q3 		– Sell
-291
Closed -$7K – 1971
2020
Q2 		$7K Buy
+291
New +$5.46K ﹤0.01% 3070

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Private Advisor Group's CYTK Position: Q2 2026 in Review

Private Advisor Group opened a new position in Cytokinetics (CYTK) in Q2 2026: 7,242 shares worth $617K. The stake represents ﹤0.01% of the portfolio and ranks #1646 among its holdings. This is a return to the name: Private Advisor Group previously reported a position in CYTK as recently as Q2 2020.

Private Advisor Group first reported a position in CYTK in Q2 2020 and has held it in 2 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Private Advisor Group held 7,242 shares of Cytokinetics worth $617K as of Q2 2026.
  • Cytokinetics was a new Private Advisor Group position in Q2 2026.
  • Cytokinetics made up ﹤0.01% of Private Advisor Group's portfolio in Q2 2026, its #1646 holding.
  • Private Advisor Group first reported a position in Cytokinetics in Q2 2020 and has held it in 2 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.